IS8540A - Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma - Google Patents
Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdómaInfo
- Publication number
- IS8540A IS8540A IS8540A IS8540A IS8540A IS 8540 A IS8540 A IS 8540A IS 8540 A IS8540 A IS 8540A IS 8540 A IS8540 A IS 8540A IS 8540 A IS8540 A IS 8540A
- Authority
- IS
- Iceland
- Prior art keywords
- tweak
- modulate
- inhibit
- adjustments
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04004094A EP1566636A1 (en) | 2004-02-23 | 2004-02-23 | Use of Tweak modulators and inhibitors for the treatment of neurological conditions |
| PCT/EP2005/001921 WO2005080972A1 (en) | 2004-02-23 | 2005-02-23 | Use of tweak modulators and inhibitors for the treatment of neurological conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS8540A true IS8540A (is) | 2006-09-15 |
Family
ID=34707372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS8540A IS8540A (is) | 2004-02-23 | 2006-09-15 | Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma |
Country Status (16)
| Country | Link |
|---|---|
| EP (2) | EP1566636A1 (is) |
| JP (1) | JP2007532482A (is) |
| KR (1) | KR20070029677A (is) |
| CN (1) | CN1985169A (is) |
| AT (1) | ATE504600T1 (is) |
| AU (1) | AU2005214843A1 (is) |
| BR (1) | BRPI0507959A (is) |
| CA (1) | CA2558770A1 (is) |
| DE (1) | DE602005027322D1 (is) |
| EA (1) | EA200601547A1 (is) |
| IL (1) | IL177285A0 (is) |
| IS (1) | IS8540A (is) |
| MX (1) | MXPA06009518A (is) |
| NO (1) | NO20064293L (is) |
| WO (1) | WO2005080972A1 (is) |
| ZA (1) | ZA200606840B (is) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE200100372A (et) | 1999-01-15 | 2002-10-15 | Biogen, Incorporated | TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks |
| CA2887716C (en) | 2002-04-09 | 2017-01-24 | Biogen Idec Ma Inc. | Methods for treating tweak-related conditions |
| AU2011239311B2 (en) * | 2005-02-17 | 2014-05-22 | Biogen Ma Inc. | Treating Neurological Disorders |
| US20090124993A1 (en) | 2005-02-17 | 2009-05-14 | Burkly Linda C | Treating neurological disorders |
| CA2607697C (en) | 2005-05-10 | 2015-01-06 | Biogen Idec Ma Inc. | Treating and evaluating inflammatory disorders |
| DK1888113T3 (da) | 2005-05-27 | 2014-09-01 | Biogen Idec Inc | Tweak-bindende antistoffer |
| WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
| EP1876448A1 (en) * | 2005-09-30 | 2008-01-09 | DIGILAB BioVisioN GmbH | Method and analytical reagents for identifying therapeutics using biomarkers responsive to thiazolidinediones. |
| EP2545938A1 (en) | 2007-08-03 | 2013-01-16 | Abbott Biotherapeutics Corp. | Therapeutic use of anti-tweak receptor antibodies |
| US9068004B2 (en) | 2010-02-04 | 2015-06-30 | University Of Louisville Research Foundation, Inc. | TWEAK/Fn14 system regulates skeletal muscle atrophy and regeneration |
| EP2683740B1 (en) | 2011-03-10 | 2018-07-04 | Omeros Corporation | Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4276110A (en) | 1978-11-30 | 1981-06-30 | Yardney Electric Corporation | Method of forming a separator integral with an electrode |
| US6379882B1 (en) * | 1998-09-14 | 2002-04-30 | Elan Pharmaceuticals, Inc. | Method for selecting compounds for treating ischemia-related cellular damage |
| EE200100372A (et) * | 1999-01-15 | 2002-10-15 | Biogen, Incorporated | TWEAK-valgu ja TWEAK-valgu retseptori antagonistid ja nende kasutamine immuunhaiguste raviks |
| JP2004508415A (ja) * | 2000-09-14 | 2004-03-18 | バイオジェン インコーポレイテッド | 抗脈管形成因子としてのtweakレセプターアゴニスト |
-
2004
- 2004-02-23 EP EP04004094A patent/EP1566636A1/en not_active Withdrawn
-
2005
- 2005-02-23 MX MXPA06009518A patent/MXPA06009518A/es not_active Application Discontinuation
- 2005-02-23 EP EP05715497A patent/EP1721157B1/en not_active Expired - Lifetime
- 2005-02-23 WO PCT/EP2005/001921 patent/WO2005080972A1/en not_active Ceased
- 2005-02-23 CN CNA2005800056025A patent/CN1985169A/zh active Pending
- 2005-02-23 AT AT05715497T patent/ATE504600T1/de not_active IP Right Cessation
- 2005-02-23 BR BRPI0507959-4A patent/BRPI0507959A/pt not_active Application Discontinuation
- 2005-02-23 CA CA002558770A patent/CA2558770A1/en not_active Abandoned
- 2005-02-23 KR KR1020067019381A patent/KR20070029677A/ko not_active Withdrawn
- 2005-02-23 DE DE602005027322T patent/DE602005027322D1/de not_active Expired - Lifetime
- 2005-02-23 AU AU2005214843A patent/AU2005214843A1/en not_active Abandoned
- 2005-02-23 EA EA200601547A patent/EA200601547A1/ru unknown
- 2005-02-23 JP JP2006553571A patent/JP2007532482A/ja active Pending
-
2006
- 2006-08-03 IL IL177285A patent/IL177285A0/en unknown
- 2006-08-15 ZA ZA200606840A patent/ZA200606840B/xx unknown
- 2006-09-15 IS IS8540A patent/IS8540A/is unknown
- 2006-09-22 NO NO20064293A patent/NO20064293L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070029677A (ko) | 2007-03-14 |
| EP1566636A1 (en) | 2005-08-24 |
| ZA200606840B (en) | 2008-05-28 |
| DE602005027322D1 (de) | 2011-05-19 |
| IL177285A0 (en) | 2006-12-10 |
| CN1985169A (zh) | 2007-06-20 |
| EP1721157A1 (en) | 2006-11-15 |
| CA2558770A1 (en) | 2005-09-01 |
| ATE504600T1 (de) | 2011-04-15 |
| NO20064293L (no) | 2006-09-22 |
| EA200601547A1 (ru) | 2006-12-29 |
| WO2005080972A1 (en) | 2005-09-01 |
| EP1721157B1 (en) | 2011-04-06 |
| MXPA06009518A (es) | 2007-03-23 |
| JP2007532482A (ja) | 2007-11-15 |
| AU2005214843A1 (en) | 2005-09-01 |
| BRPI0507959A (pt) | 2007-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI372061B (en) | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease | |
| ATE429645T1 (de) | Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| EP1481077A4 (en) | MITOTIC KINESINE HEMMER | |
| WO2007022470A3 (en) | Methods and compositions for treating neurological disease | |
| GEP20084420B (en) | Use of imidazole compounds for the treatment of neurodegenerative disorders | |
| WO2005103041A3 (en) | Treatment of cns disorders using cns target modulators | |
| BRPI0517015A (pt) | compostos e composições como inibidores de atividade de receptor 1 de canabinóide | |
| IS8540A (is) | Notkun TWEAK stilla og tálma til að meðhöndla taugasjúkdóma | |
| MA30392B1 (fr) | Composes organiques et leurs utilisations | |
| DE60312516D1 (de) | Inhibitoren von mitotischem kinesin | |
| WO2004058700A3 (en) | Mitotic kinesin inhibitors | |
| EP1551812A4 (en) | MITOTIC KINESINE HEMMER | |
| ATE480255T1 (de) | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen | |
| MY146548A (en) | Certain chemicals entities, compositions, and methods | |
| ATE446094T1 (de) | Mitotische kinesin-hemmer | |
| ATE438404T1 (de) | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien | |
| NO20080969L (no) | 1,2-diarylimidazoler for anvendelse som CBI-modulatorer | |
| UA81423C2 (en) | PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION | |
| EA200970817A1 (ru) | Лекарственная форма, содержащая 1{6-[(3-циклобутил-2,3,4,5-тетрагидро-1н-3-бензазепин-7-ил)окси]-3-пиридинил}-2-пирролидинон или его соль и стабилизатор, который уменьшает его деградацию | |
| DE602005025941D1 (de) | Alpha-Aminoamid-Derivate zur Behandlung von Suchtstörungen | |
| ATE494008T1 (de) | Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen | |
| MXPA05011699A (es) | Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior. | |
| DK1592446T3 (da) | Inhibering af CD95-ligand/receptorsystemet til behandling af neurologiske lidelser og skader | |
| DE602006012313D1 (de) | Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen |